Pharmafile Logo
Pharmafocus logo
Advanced Search

Janssen

Showing 15 posts of 276 posts found.

swine flu virus

TSRI and Janssen close in on universal flu vaccine

August 25, 2015
Manufacturing and Production Janssen, Vaccine, flu, immunology, universal flu vaccine

Scientists from Janssen and The Scripps Research Institute (TSRI) have found a way to induce antibodies to fight a wide …

News
Janssen image

European Imbruvica approval for Janssen

July 20, 2015
Medical Communications, Sales and Marketing B-cell lymphoma, EC, European Commission, Janssen, Waldenström’s Macroglobulinemia, imbruvica, rare cancer

Janssen has received final European sign-off for its oncology treatment Imbruvica (ibrutinib) as a treatment option for adult patients with …

News
Hospira image

Data supports switching to Hospira biosimilar for RA

June 10, 2015
Research and Development, Sales and Marketing EULAR, Hospira, Janssen, RA, brett wells, celltrion, inflectra, rome

Findings presented at EULAR this week from the first real-world study in patients with rheumatic diseases supports switching from J&J’s …

News
Stelara image

NICE U-turn on Janssen arthritis drug

June 4, 2015
Sales and Marketing Janssen, NICE, Stelara, psoriasis, uturn

NICE has performed a U-turn on Janssen’s Stelara and has now recommended the drug for the treatment of psoriatic arthritis. …

News
EMA image

EMA recommends eight drugs for approval

May 22, 2015
Sales and Marketing Amgen, BMS, EMA, Janssen, Merck, keytruda

The EMA has recommended eight medicines for approval in a round of reviews, including four new cancer indications. Amgen’s Repatha …

News
Velcade image

J&J blood cancer drug gets UK launch

March 25, 2015
Sales and Marketing Cancer, J&J, JJ, Janssen, NICE, Velcade, bortezomib, mcl, nhl

Johnson and Johnson’s pharma unit Janssen is launching Velcade in the UK for the first-line treatment of Mantle Cell Lymphoma …

News
Janssen image

J&J acquires Index Ventures-owned firm XO1

March 23, 2015
Sales and Marketing Index Ventures, Isis, J&J, JJ, Janssen, vectura, xo1

Johnson & Johnson’s pharma unit Janssen has acquired Index Ventures’ biopharma firm XO1 Limited that develops the promising anti-thrombin antibody …

News

NICE recommends hep C and bowel treatments

February 26, 2015
Sales and Marketing AbbVie, Humira, J&J, JJ, Janssen, Merck, Remicade, Simponi, olysio

Three drugs to treat chronic bowel condition ulcerative colitis and one for hepatitis C will be funded by the NHS …

News
J&J image

J&J leukaemia drug gets FDA go-ahead

January 30, 2015
Sales and Marketing FDA, J&J, JJ, Janssen, The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s macroglobulinemia (WM) – a rare indol, Waldenström’s Macroglobulinemia, ibrutinab, imbruvica, johnson

The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s …

News
Vaccine image

Pharma firms pledge vaccine support for developing countries

January 27, 2015
Manufacturing and Production, Research and Development, Sales and Marketing GAVI, GSK, Janssen, Médecins Sans Frontières, Pfizer, Vaccine

Several pharma firms have announced commitments to help Gavi, the global vaccine alliance, to increase immunisation of children in developing …

News
J&J image

Olysio and Xarelto boost J&J’s Q4

January 21, 2015
Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four

Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …

News
Olysio image

Janssen privy to new pricing scheme and see NICE nod

January 16, 2015
Sales and Marketing Janssen, NHS, NICE, hep C, hepatitis, olysio, ribavirin, simeprevir

Janssen’s hepatitis C drug Olysio has been approved by NICE whilst also reaching a novel ‘pay if you clear’ pricing …

News
Janssen image

Isis and J&J sign RNA deal

January 8, 2015
Research and Development, Sales and Marketing Isis, J&J, JJ, Janssen, RNA, gastrointestinal tract

Isis Pharmaceuticals is collaborating with Johnson & Johnson’s pharma unit Janssen to develop antisense drugs to treat autoimmune disorders. The …

News
Janssen image

Vectura and J&J shake on asthma/COPD deal

January 6, 2015
Research and Development, Sales and Marketing COPD, J&J, JJ, Janssen, asthma, johnson, rezolsta, tybost, vectura

British firm Vectura has entered an agreement with Johnson & Johnson’s pharma unit Janssen to develop therapies for asthma and …

News
Janssen image

Janssen launches HIV combination pill

December 17, 2014
Research and Development, Sales and Marketing BMS, Gilead, HIV, Janssen, NHS, NICE, rezolsta, tybost

Janssen has launched its HIV therapy Rezolsta in the UK, which combines its own Prezista with Gilead’s Tybost. Prezista (darunavir) …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025